Decreased chronic cellular and antibody-mediated injury in the kidney following simultaneous liver-kidney transplantation

Timucin Taner, Julie K. Heimbach, Charles B. Rosen, Scott Nyberg, Walter D. Park, Mark D Stegall

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

In simultaneous liver-kidney transplantation (SLK), the liver can protect the kidney from hyperacute rejection and may also decrease acute cellular rejection rates. Whether the liver protects against chronic injury is unknown. To answer this we studied renal allograft surveillance biopsies in 68 consecutive SLK recipients (14 with donor-specific alloantibodies at transplantation [DSA+], 54 with low or no DSA, [DSA-]). These were compared with biopsies of a matched cohort of kidney transplant alone (KTA) recipients (28 DSA+, 108 DSA-). Overall 5-year patient and graft survival was not different: 93.8% and 91.2% in SLK, and 91.9% and 77.1% in KTA. In DSA+ recipients, KTA had a significantly higher incidence of acute antibody-mediated rejection (46.4% vs. 7.1%) and chronic transplant glomerulopathy (53.6% vs. 0%). In DSA- recipients at 5 years, KTA had a significantly higher cumulative incidence of T cell-mediated rejection (clinical plus subclinical, 30.6% vs. 7.4%). By 5 years, DSA+ KTA had a 44% decline in mean GFR while DSA+SLK had stable GFR. In DSA- KTA, the incidence of a combined endpoint of renal allograft loss or over a 50% decline in GFR was significantly higher (20.4% vs. 7.4%). Simultaneously transplanted liver allograft was the most predictive factor for a significantly lower incidence of cellular (odds ratio 0.13, 95% confidence interval 0.06-0.27) and antibody-mediated injury (odds ratio 0.11, confidence interval 0.03-0.32), as well as graft functional decline (odds ratio 0.22, confidence interval 0.06-0.59). Thus, SLK is associated with reduced chronic cellular and antibody-mediated alloimmune injury in the kidney allograft.

Original languageEnglish (US)
Pages (from-to)909-917
Number of pages9
JournalKidney International
Volume89
Issue number4
DOIs
StatePublished - Apr 1 2016

Fingerprint

Liver Transplantation
Kidney Transplantation
Kidney
Antibodies
Wounds and Injuries
Transplants
Allografts
Odds Ratio
Incidence
Confidence Intervals
Liver
Biopsy
Isoantibodies
Graft Survival
Transplantation
Tissue Donors
T-Lymphocytes

Keywords

  • alloimmunity
  • antibody-mediated rejection
  • immunoregulation
  • kidney rejection
  • long-term outcomes
  • simultaneous liver-kidney transplantation

ASJC Scopus subject areas

  • Nephrology

Cite this

Decreased chronic cellular and antibody-mediated injury in the kidney following simultaneous liver-kidney transplantation. / Taner, Timucin; Heimbach, Julie K.; Rosen, Charles B.; Nyberg, Scott; Park, Walter D.; Stegall, Mark D.

In: Kidney International, Vol. 89, No. 4, 01.04.2016, p. 909-917.

Research output: Contribution to journalArticle

@article{7a116ae901714d57b9c55be8d8d5b777,
title = "Decreased chronic cellular and antibody-mediated injury in the kidney following simultaneous liver-kidney transplantation",
abstract = "In simultaneous liver-kidney transplantation (SLK), the liver can protect the kidney from hyperacute rejection and may also decrease acute cellular rejection rates. Whether the liver protects against chronic injury is unknown. To answer this we studied renal allograft surveillance biopsies in 68 consecutive SLK recipients (14 with donor-specific alloantibodies at transplantation [DSA+], 54 with low or no DSA, [DSA-]). These were compared with biopsies of a matched cohort of kidney transplant alone (KTA) recipients (28 DSA+, 108 DSA-). Overall 5-year patient and graft survival was not different: 93.8{\%} and 91.2{\%} in SLK, and 91.9{\%} and 77.1{\%} in KTA. In DSA+ recipients, KTA had a significantly higher incidence of acute antibody-mediated rejection (46.4{\%} vs. 7.1{\%}) and chronic transplant glomerulopathy (53.6{\%} vs. 0{\%}). In DSA- recipients at 5 years, KTA had a significantly higher cumulative incidence of T cell-mediated rejection (clinical plus subclinical, 30.6{\%} vs. 7.4{\%}). By 5 years, DSA+ KTA had a 44{\%} decline in mean GFR while DSA+SLK had stable GFR. In DSA- KTA, the incidence of a combined endpoint of renal allograft loss or over a 50{\%} decline in GFR was significantly higher (20.4{\%} vs. 7.4{\%}). Simultaneously transplanted liver allograft was the most predictive factor for a significantly lower incidence of cellular (odds ratio 0.13, 95{\%} confidence interval 0.06-0.27) and antibody-mediated injury (odds ratio 0.11, confidence interval 0.03-0.32), as well as graft functional decline (odds ratio 0.22, confidence interval 0.06-0.59). Thus, SLK is associated with reduced chronic cellular and antibody-mediated alloimmune injury in the kidney allograft.",
keywords = "alloimmunity, antibody-mediated rejection, immunoregulation, kidney rejection, long-term outcomes, simultaneous liver-kidney transplantation",
author = "Timucin Taner and Heimbach, {Julie K.} and Rosen, {Charles B.} and Scott Nyberg and Park, {Walter D.} and Stegall, {Mark D}",
year = "2016",
month = "4",
day = "1",
doi = "10.1016/j.kint.2015.10.016",
language = "English (US)",
volume = "89",
pages = "909--917",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Decreased chronic cellular and antibody-mediated injury in the kidney following simultaneous liver-kidney transplantation

AU - Taner, Timucin

AU - Heimbach, Julie K.

AU - Rosen, Charles B.

AU - Nyberg, Scott

AU - Park, Walter D.

AU - Stegall, Mark D

PY - 2016/4/1

Y1 - 2016/4/1

N2 - In simultaneous liver-kidney transplantation (SLK), the liver can protect the kidney from hyperacute rejection and may also decrease acute cellular rejection rates. Whether the liver protects against chronic injury is unknown. To answer this we studied renal allograft surveillance biopsies in 68 consecutive SLK recipients (14 with donor-specific alloantibodies at transplantation [DSA+], 54 with low or no DSA, [DSA-]). These were compared with biopsies of a matched cohort of kidney transplant alone (KTA) recipients (28 DSA+, 108 DSA-). Overall 5-year patient and graft survival was not different: 93.8% and 91.2% in SLK, and 91.9% and 77.1% in KTA. In DSA+ recipients, KTA had a significantly higher incidence of acute antibody-mediated rejection (46.4% vs. 7.1%) and chronic transplant glomerulopathy (53.6% vs. 0%). In DSA- recipients at 5 years, KTA had a significantly higher cumulative incidence of T cell-mediated rejection (clinical plus subclinical, 30.6% vs. 7.4%). By 5 years, DSA+ KTA had a 44% decline in mean GFR while DSA+SLK had stable GFR. In DSA- KTA, the incidence of a combined endpoint of renal allograft loss or over a 50% decline in GFR was significantly higher (20.4% vs. 7.4%). Simultaneously transplanted liver allograft was the most predictive factor for a significantly lower incidence of cellular (odds ratio 0.13, 95% confidence interval 0.06-0.27) and antibody-mediated injury (odds ratio 0.11, confidence interval 0.03-0.32), as well as graft functional decline (odds ratio 0.22, confidence interval 0.06-0.59). Thus, SLK is associated with reduced chronic cellular and antibody-mediated alloimmune injury in the kidney allograft.

AB - In simultaneous liver-kidney transplantation (SLK), the liver can protect the kidney from hyperacute rejection and may also decrease acute cellular rejection rates. Whether the liver protects against chronic injury is unknown. To answer this we studied renal allograft surveillance biopsies in 68 consecutive SLK recipients (14 with donor-specific alloantibodies at transplantation [DSA+], 54 with low or no DSA, [DSA-]). These were compared with biopsies of a matched cohort of kidney transplant alone (KTA) recipients (28 DSA+, 108 DSA-). Overall 5-year patient and graft survival was not different: 93.8% and 91.2% in SLK, and 91.9% and 77.1% in KTA. In DSA+ recipients, KTA had a significantly higher incidence of acute antibody-mediated rejection (46.4% vs. 7.1%) and chronic transplant glomerulopathy (53.6% vs. 0%). In DSA- recipients at 5 years, KTA had a significantly higher cumulative incidence of T cell-mediated rejection (clinical plus subclinical, 30.6% vs. 7.4%). By 5 years, DSA+ KTA had a 44% decline in mean GFR while DSA+SLK had stable GFR. In DSA- KTA, the incidence of a combined endpoint of renal allograft loss or over a 50% decline in GFR was significantly higher (20.4% vs. 7.4%). Simultaneously transplanted liver allograft was the most predictive factor for a significantly lower incidence of cellular (odds ratio 0.13, 95% confidence interval 0.06-0.27) and antibody-mediated injury (odds ratio 0.11, confidence interval 0.03-0.32), as well as graft functional decline (odds ratio 0.22, confidence interval 0.06-0.59). Thus, SLK is associated with reduced chronic cellular and antibody-mediated alloimmune injury in the kidney allograft.

KW - alloimmunity

KW - antibody-mediated rejection

KW - immunoregulation

KW - kidney rejection

KW - long-term outcomes

KW - simultaneous liver-kidney transplantation

UR - http://www.scopus.com/inward/record.url?scp=84964584144&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964584144&partnerID=8YFLogxK

U2 - 10.1016/j.kint.2015.10.016

DO - 10.1016/j.kint.2015.10.016

M3 - Article

C2 - 26924059

AN - SCOPUS:84964584144

VL - 89

SP - 909

EP - 917

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 4

ER -